The Food and Drug Administration’s Center for Drug Evaluation and Research is providing an update to key leadership positions within the Office of Generic Drugs, the agency announced.
There is “something brewing in Congress” these days, NACDS president and CEO Steve Anderson wrote in a July 16 newsletter to NACDS chain members.
Mylan on Thursday announced that the U.S. District Court for the district of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline in relation to paroxetine CR, the generic version of GSK's Paxil CR.
Current programs to dispose of unused medicines in the home are sufficient, argued representatives of industry in appealing a provision put into place by a San Francisco-area county that would place the burden of recapturing these medicines on the manufacturer.
The National Association of Chain Drug Stores on Tuesday put forward pharmacy-specific solutions as the Senate Finance Committee conducted a hearing on “Chronic Illness: Addressing Patients’ Unmet Needs.”
Former Republican Speaker of the House J. Dennis Hastert last week wrote an editorial for the Washington Times supporting the use of such tamper-resistant pseudoephedrine products as Acura Pharmaceuticals' Nexafed and Westport Pharmaceuticals' Zephrex-D.
Teva Pharmaceuticals on Monday announced that the Food and Drug Administration has accepted the company's new drug application for albuterol multi-dose dry-powder inhaler, a breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.
Anacor Pharmaceuticals announced that the Food and Drug Administration has approved the company's new drug application for Kerydin (tavaborole) topical solution, 5% — an antifungal approved for the topical treatment of onychomycosis of the toenails.
A survey co-released by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that 8-in-10 healthcare providers have serious concerns about a proposed Food and Drug Administration rule on generic drug labeling.
A wave of new drug introductions and healthcare policy changes has had a significant impact on women’s health care over the past year.